Genmab | GEN - Operating Expenses



Genmab reported DKK565M in Operating Expenses for its fiscal quarter ending in June of 2025.


Operating Expenses Change Date
Agios Pharmaceuticals USD 139.51M 24.16M Jun/2025
Almirall EUR 517.43M 265.53M Jun/2025
Amarin USD 58.77M 56.06M Mar/2025
Amgen USD 6.52B 337M Jun/2025
argenx SE USD 744.12M 92.38M Jun/2025
AstraZeneca USD 10.95B 1.04B Jun/2025
Bayer EUR 10.73B 688M Jun/2025
BioMarin Pharmaceutical USD 548.52M 27.27M Jun/2025
Demant DKK 9.39B 392M Jun/2025
Exelixis USD 354.68M 13.9M Jul/2025
Fresenius Medical Care EUR 4.36B 189M Jun/2025
Galapagos EUR 122.32M 111.37M Jun/2025
Genmab DKK 565M 38M Jun/2025
GlaxoSmithKline GBP 5.96B 663M Jun/2025
GN Store Nord DKK 3.7B 72M Jun/2025
GRIFOLS EUR 1.54B 24.64M Jun/2025
Hikma Pharmaceutical USD 1.31B 63M Dec/2024
Insmed USD 361.29M 20.33M Jun/2025
Lonza CHF 3.09B 564M Dec/2024
Merck EUR 4.22B 49M Jun/2025
Novartis USD 9.97B 1.02B Jun/2025
Regeneron Pharmaceuticals USD 2.6B 159.1M Jun/2025
Roche Holding CHF 11.43B 1.48B Dec/2024
Sanofi EUR 9.02B 702M Jun/2025
UCB EUR 2.36B 108M Dec/2024